IVVD Q3 2024 Earnings — Invivyd, Inc. Revenue & Financial Results | Market Cap Arena

IVVDInvivyd, Inc.

$257M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M

Gross Profit

$8M91.3% margin

Operating Income

-$62M-670.0% margin

Net Income

-$61M-653.1% margin

EPS (Diluted)

$-0.51

QoQ Revenue Growth

+310.8%

Cash Flow

Operating Cash Flow

-$41M

Free Cash Flow

-$41M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$162M

Total Liabilities

$79M

Stockholders' Equity

$83M

Cash & Equivalents

$107M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$0	—
Gross Profit	$8M	$0	—
Operating Income	-$62M	-$43M	-44.7%
Net Income	-$61M	-$39M	-54.0%

Revenue Segments

Product

$9M100%